Skip to main content
. 2023 Feb 23;12(3):386–403. doi: 10.21037/hbsn-22-421

Figure 1.

Figure 1

Flow diagram of the Delphi process adopted for the development of consensus statements on MAFLD and the risk of CKD. MAFLD, metabolic dysfunction-associated fatty liver disease; CKD, chronic kidney disease; R1, round 1; R2, round 2.